Clinical Trial Update: The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the efficacy and safety of Luphere Depot Inj. 3.75mg (leuprolide acetate) in central precocious puberty has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty

Drugs mentioned

• Luphere Depot Inj. 3.75mg (Leuprolide Acetate 3.75 mg)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Central Precocious Puberty | Phase 4 | Status: COMPLETED